December 5, 2008 - The ability for cancer cells to reverse a natural self-destruction process may attribute to the reason cancer can return after treatment, according to new research published in the British Journal of Cancer.

Apoptosis is a type of programmed cell suicide that allows the body to rid itself of damaged and potentially dangerous cells. In the recent study, led by Professor Ming-Chiu Fung, from the Chinese University of Hong Kong, researchers showed that cancer cells can reverse this process, regaining their shape and function while continuing to divide.

In the study, chemicals used on human cervical, skin, liver and breast cancer cells initiated apoptosis. Normally, there is a "point of no return" in most cells where they are driven to suicide, even when the death trigger is removed, but researchers found cancer cells crossing this point were still able to recover once the suicide-inducing chemicals had been eliminated.

They only failed to survive once the nuclei containing the bulk of their DNA began to disintegrate, an event right at the end of the cell suicide process.

According to Fung, the finding provides new clues as to what drives cancer cells to come back to life after chemotherapy treatment, and to what extent the ability for cancer cells to reverse cell death contributes to their continued division and growth during cycles of anticancer treatment.

Source: British Journal of Cancer

For more information: www.nature.com/bjc


Related Content

News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Technology | Focused Ultrasound Therapy

Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of Exablate Neuro to include the treatment of patients with tremor-dominant Parkinson's disease (PD).

Time December 21, 2018
arrow
Videos | Radiation Oncology

Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation ...

Time November 06, 2018
arrow
News | Radiation Dose Management

AngioDynamics Inc. announced an agreement to acquire RadiaDyne, a privately held medical diagnostic and device company that designs and develops patient dose monitoring technology to improve cancer treatment outcomes.

Time September 24, 2018
arrow
News | Radiation Oncology

World Cancer Day takes place annually on Feb. 4 to raise awareness and education in the media, governments and people ...

Time February 01, 2018
arrow
News | Oncology Related Products

December 19, 2016 — Children’s National Health System and Celsion Corp. announced in November the launch of a clinical ...

Time December 19, 2016
arrow
News | Clinical Decision Support

October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use ...

Time October 27, 2016
arrow
News | Ultrasound Imaging

September 12, 2016 — Tiny microbubbles are being used to more effectively identify liver tumors, according to a study ...

Time September 12, 2016
arrow
Subscribe Now